Objectives The authors sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by ¹⁸F-Fluorodeoxyglucose (¹⁸F-FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI.

Background PSO, a chronic inflammatory skin disease, is associated with VI by ¹⁸F-FDG PET/CT and increased cardiometabolic risk including adipose tissue dysregulation. Recently, VI was associated with future cardiovascular events; however, the relationship of visceral and subcutaneous adiposity with VI in PSO has yet to be evaluated.

Methods Consecutive PSO patients (N = 77) underwent ¹⁸F-FDG PET/CT scans to measure VI and abdominal adiposity. A subset of PSO patients with severe skin disease was scanned at 1 year following PSO treatment (N = 13).

Results The cohort was middle aged (51.8 ± 12.6 years), predominantly male (n = 44, 57%), had low cardiovascular risk by Framingham 10-year risk (median 4 years [interquartile range (IQR): 2 to 7 years]), and mild-to-moderate skin disease (5.2 [IQR: 3.0 to 8.5]). PSO disease severity associated with VAT (β = 0.33; p = 0.004) beyond SAT (β = 0.30; p = 0.005). VAT (β = 0.55; p < 0.001), but not SAT (β = 0.15; p = 0.11), associated with VI beyond cardiovascular risk factors. We followed a subset of severe PSO patients treated aggressively for PSO and observed improvement in PSO severity and VAT, which was associated with an improvement in VI at 1 year beyond cardiovascular risk factors (β = 0.53; p = 0.049).

Conclusions Volume-based CT measurement of VAT may capture metabolic risk associated with VI compared to subcutaneous adipose tissue in PSO. PSO treatment associated with a decrease in VAT as well as decrease in VI suggesting VAT as a relevant biomarker related to VI in PSO.

目的作者试图通过银屑病（PSO）中的¹⁸ F-氟脱氧葡萄糖（¹⁸ F-FDG）正电子发射断层扫描（PET）/计算机断层扫描（CT）检查内脏脂肪组织（VAT）与血管炎症（VI）之间的关系。。此外，我们评估了PSO的处理是否可调节VAT和VI。

背景PSO是一种慢性炎症性皮肤病，通过¹⁸ F-FDG PET / CT与VI相关，并增加了包括脂肪组织失调在内的心脏代谢风险。最近，VI与未来的心血管事件有关。然而，内脏和皮下肥胖与PSO中VI的关系尚待评估。

方法连续的PSO患者（N = 77）接受^18次F-FDG PET / CT扫描，以测量VI和腹部肥胖。PSO治疗后1年对一部分PSO严重皮肤病患者进行了扫描（N = 13）。

结果该队列人群为中年（51.8±12.6岁），主要为男性（n = 44，57％），因弗雷明汉（Framingham）的10年风险（中位4年[四分位间距（IQR）：2至7岁]）的心血管风险较低。 ）和轻度至中度的皮肤病（5.2 [IQR：3.0至8.5]）。与VAT（β= 0.33; p = 0.004）相关的PSO疾病严重程度超过SAT（β= 0.30; p = 0.005）。VAT（β= 0.55; p <0.001），而不是SAT（β= 0.15; p = 0.11），与超出心血管危险因素的VI相关。我们追踪了一组积极接受PSO治疗的严重PSO患者，并观察到PSO严重性和增值税有所改善，这与心血管疾病危险因素后1年时VI的改善相关（β= 0.53； p = 0.049）。

结论与PSO皮下脂肪组织相比，基于体积的CT测量VAT可以捕获与VI相关的代谢风险。PSO治疗与增值税的减少以及VI的减少相关，这表明增值税是PSO中与VI相关的相关生物标志物。